Skip to main content

Table 4 Complement modulation in AIHA treatment: now and in the future

From: Autoimmune hemolytic anemia: current knowledge and perspectives

Level of complement pathway modulation Novel agents Comments
C1 complex (C1q, C1r, C1s) ANX005 anti-C1q monoclonal antibody
TNT003 anti-C1s monoclonal antibody
PIC1 peptide inhibitor
Sutimlimab anti-C1s monoclonal antibody
C3 complement Compstatin Cp40 long-acting form polyethylene glycol
Pegcetacoplan (APL2) pegylated compstatin analog
C5 complement Eculizumab anti-C5 monoclonal antibody